Takeda Pharmaceutical Company Limited (TYO:4502)

Japan flag Japan · Delayed Price · Currency is JPY
4,261.00
+31.00 (0.73%)
Aug 8, 2025, 2:45 PM JST
0.73%
Market Cap6.61T
Revenue (ttm)4.48T
Net Income (ttm)136.92B
Shares Out1.56B
EPS (ttm)85.30
PE Ratio49.59
Forward PE31.32
Dividend200.00 (4.72%)
Ex-Dividend DateSep 29, 2025
Volume3,811,100
Average Volume4,575,610
Open4,246.00
Previous Close4,230.00
Day's Range4,222.00 - 4,274.00
52-Week Range3,916.00 - 4,573.00
Beta0.27
RSI46.27
Earnings DateJul 30, 2025

About TYO:4502

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A... [Read more]

Sector Healthcare
Founded 1781
Employees 47,455
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4502
Full Company Profile

Financial Performance

In 2024, TYO:4502's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial Statements

News

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...

6 days ago - CNBC Television

President Trump demands drugmakers slash prices within 60 days

CNBC's Joe Kernen reports on the latest news.

6 days ago - CNBC Television

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

Takeda Pharmaceutical Company Limited (NYSE: TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), ref...

8 days ago - Benzinga

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

Takeda Pharmaceutical Company Limited TAK posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a...

8 days ago - Benzinga

Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression

OSAKA, Japan--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) today announced earnings results for the first quarter of fiscal year 2025 (three months ended June 30, 2025), with generic erosion of VYVAN...

8 days ago - Business Wire

Insights Ahead: Takeda Pharmaceutical's Quarterly Earnings

Takeda Pharmaceutical (NYSE: TAK) is gearing up to announce its quarterly earnings on Wednesday, 2025-07-30. Here's a quick overview of what investors should know before the release. Analysts are est...

9 days ago - Benzinga

Takeda Receives FDA 510(k) Clearance for HyHubTM and HyHubTM Duo Devices to Simplify HYQVIA® Administration

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for HyHubTM and HyHubTM Duo, ...

17 days ago - Business Wire

Takeda: Positioned To Tackle Future Clinical Demand In A Highly Regulated Sector

In my followup on Takeda Pharmaceutical Co (TAK), I am reaffirming my buy rating from March. Clinical demand in multiple areas, along with an active drug pipeline, could keep driving the top-line desp...

21 days ago - Seeking Alpha

Takeda Announces Positive Results from Two Pivotal Phase 3 Studies of Oveporexton (TAK-861) in Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that all primary and secondary endpoints were met in two Phase 3 randomized, double-blind, placebo-controll...

24 days ago - Business Wire

Takeda Announces U.S. FDA Approval of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved GAMMAGARD LIQUID ERC [immune globulin infusio...

5 weeks ago - Business Wire

Takeda Announces New Assignments of Directors

OSAKA, Japan & CAMBRIDGE, Mass. — Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meeting of Sharehold...

6 weeks ago - Financial Post

Takeda Announces New Assignments of Directors

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TOKYO:4502/NYSE:TAK) has announced new assignments of directors, determined at the Board of Directors meeting, following the 149th Annual Meet...

6 weeks ago - Business Wire

European Commission Approves ADCETRIS® (brentuximab vedotin) for the Treatment of Adult Patients with Newly Diagnosed Stage IIb/III/IV Hodgkin Lymphoma in Combination with ECADD

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, c...

2 months ago - Business Wire

Protagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia Vera

NEWARK, Calif. & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announced detailed results from the Phase...

2 months ago - Business Wire

Takeda and Nature Announce Call for Applications Now Open for 2026 Innovators in Science Award

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Applications are now open for the Takeda Innovators in Science Award with Nature recognizing the groundbreaking research of early-career scientists.

2 months ago - Business Wire

The New England Journal of Medicine Publishes Data from Phase 2b Trial of Oral Orexin Receptor 2 Agonist Oveporexton (TAK-861) in People with Narcolepsy Type 1

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE: 4502/NYSE:TAK) today announced that the New England Journal of Medicine published data from the Phase 2b trial of oveporexton (TAK-861) i...

3 months ago - Business Wire

Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO

Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the next five years, saying the U.S. market remain crucial for the Japanese drug...

3 months ago - CNBC International TV

Takeda Pharma less impacted by tariff, yen headwinds than other Japanese drugmakers: CEO

Christophe Weber, CEO of Takeda Pharma, discusses the group's plans to invest $30 billion into its U.S. operations over the next five years, saying the U.S. market remain crucial for the Japanese drug...

3 months ago - CNBC

Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs

Takeda Pharmaceutical Company Limited (NYSE: TAK) reported a fiscal year 2024 net profit of 107.9 billion yen (around $709.86 million), down 25.1% year over year . Core net profit increased 2.5% (dow...

3 months ago - Benzinga

Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs

Takeda Pharmaceutical Company Limited TAK reported a fiscal year 2024 net profit of 107.9 billion yen (around $709.86 million), down 25.1% year over year.

3 months ago - Benzinga

Earnings Scheduled For May 8, 2025

Companies Reporting Before The Bell • Sempra (NYSE: SRE) is likely to report quarterly earnings at $1.32 per share on revenue of $3.92 billion. • Warner Music Gr (NASDAQ: WMG) is projected to report...

3 months ago - Benzinga